Press coverage about Spectrum Pharmaceuticals (NASDAQ:SPPI) has trended somewhat positive recently, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Spectrum Pharmaceuticals earned a news sentiment score of 0.04 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 100 out of 100, meaning that recent news coverage is extremely likely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Sees Unusual Trading Volume in Its Shares – Modern Readers (modernreaders.com)
- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Sees Significantly Higher Trading Volume – Modern Readers (modernreaders.com)
- Spectrum Pharmaceuticals, Inc. : Investor Network: Spectrum Pharmaceuticals, Inc. to Host Earnings Call (4-traders.com)
- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS (americanbankingnews.com)
- Why Spectrum Pharmaceuticals Stock Is Bolting Higher Today (fool.com)
A number of equities research analysts have issued reports on SPPI shares. Zacks Investment Research upgraded shares of Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, June 6th. ValuEngine upgraded shares of Spectrum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, May 11th. Jefferies Group LLC increased their target price on shares of Spectrum Pharmaceuticals from $8.50 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, May 3rd. HC Wainwright set a $10.00 target price on shares of Spectrum Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, May 6th. Finally, BidaskClub lowered shares of Spectrum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $8.90.
Shares of Spectrum Pharmaceuticals (SPPI) traded up 0.67% during midday trading on Tuesday, hitting $9.01. 1,021,681 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $7.52 and its 200-day moving average is $6.43. Spectrum Pharmaceuticals has a 1-year low of $3.21 and a 1-year high of $9.27. The stock’s market cap is $707.49 million.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. Spectrum Pharmaceuticals had a negative net margin of 59.33% and a negative return on equity of 30.95%. The business had revenue of $34.30 million for the quarter, compared to analysts’ expectations of $30.50 million. During the same period in the previous year, the company posted ($0.35) earnings per share. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. Analysts predict that Spectrum Pharmaceuticals will post ($1.03) earnings per share for the current fiscal year.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.